Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239.

Komaki R, Paulus R, Ettinger DS, Videtic GM, Bradley JD, Glisson BS, Langer CJ, Sause WT, Curran WJ Jr, Choy H.

Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):e531-6. doi: 10.1016/j.ijrobp.2012.01.075. Epub 2012 May 5.

2.

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.

Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, Bezjak A, Cardenal F, Fournel P, Harden S, Le Pechoux C, McMenemin R, Mohammed N, O'Brien M, Pantarotto J, Surmont V, Van Meerbeeck JP, Woll PJ, Lorigan P, Blackhall F; CONVERT Study Team.

Lancet Oncol. 2017 Aug;18(8):1116-1125. doi: 10.1016/S1470-2045(17)30318-2. Epub 2017 Jun 20.

3.

Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.

Chen GY, Jiang GL, Wang LJ, Qian H, Fu XL, Yang H, Wu KL, Zhao S.

Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):70-5.

PMID:
15629596
4.

Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222.

Le QT, Moon J, Redman M, Williamson SK, Lara PN Jr, Goldberg Z, Gaspar LE, Crowley JJ, Moore DF Jr, Gandara DR.

J Clin Oncol. 2009 Jun 20;27(18):3014-9. doi: 10.1200/JCO.2008.21.3868. Epub 2009 Apr 13.

5.
6.

[A Phase I/II Study of Chemotherapy Concurrent with Twice-daily Radiotherapy 
Schedules by Intensity Modulated Radiation Therapy Using Simultaneous Integrated Boost for Limited-stage Small Cell Lung Cancer].

You J, Yu H, Song M, Shi C, Wang X, Zheng Y, Yu R, Shi A, Zhu G.

Zhongguo Fei Ai Za Zhi. 2017 Jan 20;20(1):28-34. doi: 10.3779/j.issn.1009-3419.2017.01.04. Chinese.

7.

Irinotecan plus cisplatin chemotherapy followed by concurrent thoracic irradiation with low-dose weekly cisplatin for limited-disease small-cell lung cancer.

Wahba HA, Halim AA, El-Hadaad HA.

Med Oncol. 2012 Mar;29(1):199-204. doi: 10.1007/s12032-010-9772-0. Epub 2010 Dec 8.

PMID:
21140241
8.

Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer.

Komaki R, Shin DM, Glisson BS, Fossella FV, Murphy WK, Garden AS, Oswald MJ, Hong WK, Roth JA, Peters LJ, et al.

Int J Radiat Oncol Biol Phys. 1995 Feb 15;31(4):807-11.

PMID:
7860392
10.

Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206.

Kelley MJ, Bogart JA, Hodgson LD, Ansari RH, Atkins JN, Pang H, Green MR, Vokes EE.

J Thorac Oncol. 2013 Jan;8(1):102-8. doi: 10.1097/JTO.0b013e31827628e1.

11.

Phase 2 study of accelerated hypofractionated thoracic radiation therapy and concurrent chemotherapy in patients with limited-stage small-cell lung cancer.

Xia B, Hong LZ, Cai XW, Zhu ZF, Liu Q, Zhao KL, Fan M, Mao JF, Yang HJ, Wu KL, Fu XL.

Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):517-23. doi: 10.1016/j.ijrobp.2014.09.042. Epub 2014 Dec 3.

PMID:
25481679
13.

Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China.

Su S, Li T, Lu B, Wang X, Li J, Chen M, Lu Y, Bai Y, Hu Y, Ouyang W, Ma Z, Li Q, Li H, Wang Y.

Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):769-77. doi: 10.1016/j.ijrobp.2015.08.012. Epub 2015 Aug 7.

14.

Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.

Kubota K, Hida T, Ishikura S, Mizusawa J, Nishio M, Kawahara M, Yokoyama A, Imamura F, Takeda K, Negoro S, Harada M, Okamoto H, Yamamoto N, Shinkai T, Sakai H, Matsui K, Nakagawa K, Shibata T, Saijo N, Tamura T; Japan Clinical Oncology Group.

Lancet Oncol. 2014 Jan;15(1):106-13. doi: 10.1016/S1470-2045(13)70511-4. Epub 2013 Dec 3.

PMID:
24309370
15.

Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.

Ettinger DS, Berkey BA, Abrams RA, Fontanesi J, Machtay M, Duncan PJ, Curran WJ Jr, Movsas B, Byhardt RW; Radiation Therapy Oncology Group 9609.

J Clin Oncol. 2005 Aug 1;23(22):4991-8. Epub 2005 Jun 6.

PMID:
15939930
17.

Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903.

Kubota K, Nishiwaki Y, Sugiura T, Noda K, Mori K, Kawahara M, Negoro S, Watanabe K, Imamura F, Tamura T, Saijo N.

Clin Cancer Res. 2005 Aug 1;11(15):5534-8.

18.

Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group.

Ariyoshi Y, Fukuoka M, Furuse K, Saijo N, Ikegami H, Nishiwaki Y, Tamura T, Shimoyama M, Suemasu K.

Jpn J Clin Oncol. 1994 Oct;24(5):275-81.

PMID:
7967106
19.
20.

Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study.

Le QT, McCoy J, Williamson S, Ryu J, Gaspar LE, Edelman MJ, Dakhil SR, Sides SD, Crowley JJ, Gandara DR; Southwest oncology group.

Clin Cancer Res. 2004 Aug 15;10(16):5418-24.

Supplemental Content

Support Center